Exposure–response analyses of liraglutide 3.0 mg for weight management

@inproceedings{Wilding2016ExposureresponseAO,
  title={Exposure–response analyses of liraglutide 3.0 mg for weight management},
  author={John P H Wilding and Rune Viig Overgaard and Lisbeth Vesterg{\aa}rd Jacobsen and Christine Bj{\o}rn Jensen and Carel W le Roux},
  booktitle={Diabetes, obesity & metabolism},
  year={2016}
}
AIMS Liraglutide 3.0 mg, an acylated GLP-1 analogue approved for weight management, lowers body weight through decreased energy intake. We conducted exposure-response analyses to provide important information on individual responses to given drug doses, reflecting inter-individual variations in drug metabolism, absorption and excretion. METHODS We report efficacy and safety responses across a wide range of exposure levels, using data from one phase II (liraglutide doses 1.2, 1.8, 2.4 and 3.0… CONTINUE READING
BETA
4
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

Scientific report: a case of acute pancreatitis due to liraglutide.

  • Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 29 REFERENCES

of Health and Human Services, FDA, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER)

US Departmen
  • FDA Guidance for Industry. Population Pharmacokinetics. February 1999. Available from URL: http://www.fda.gov/downloads/ Drugs/... /Guidances/UCM072137.pdf. Accessed 21 January
  • 2016
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

for Contrave (bupropion/naltrexone) EMDAC meeting, 07 December 2010

FDA Briefing Documen
  • Available from URL: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Endocrinologicand MetabolicDrugsAdvisoryCommittee/UCM235671.pdf. Accessed 21 January
  • 2016
VIEW 1 EXCERPT

for Liraglutide, NDA 206321

FDA Briefing Documen
  • Endocrinologic and Metabolic Drugs Advisory Committee meeting, 11 September 2014. Available from URL: http://www.fda.gov/downloads/Advisory Committees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolic DrugsAdvisoryCommittee/UCM413317.pdf. Accessed 21 January
  • 2016
VIEW 1 EXCERPT

for Zimulti (rimonabant) EMDAC meeting 13 Jun 2007

FDA Briefing Documen
  • Available from URL: http://www.fda.gov/ohrms/dockets/ac/07/briefing/20074306b1-fda-backgrounder.pdf. Accessed 21 January
  • 2016
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…